Sorry, you need to enable JavaScript to visit this website.



Vaccines are one of the greatest public health advancements of all time, resulting in the control, elimination, or near-elimination of numerous infectious diseases that were once pervasive and often fatal. Pfizer has a rich history in vaccine research and development. Over the years, we’ve played a pivotal role in eliminating or nearly eliminating deadly infectious diseases like smallpox and polio globally. We have designed novel vaccines based on new delivery systems and technologies that have resulted in vaccines to prevent bacterial infections, like those caused by S. pneumoniae and N. meningitidis.

Today, more people are benefiting from safe and efficacious vaccines to prevent infectious diseases than ever before, and vaccines provide essential health benefits at all ages, from maternal and infant populations to seniors. However, our work is not done given the many infectious diseases remaining with a high unmet medical need and a growing list of vaccine preventable diseases.
It is an exciting time in vaccine research and development, as scientific discoveries, technological advancements and regulatory paradigms are paving the way for novel vaccines. While Pfizer’s Vaccine Research and Development scientists continue to extend our leadership position in pneumococcal and meningococcal disease prevention, they are also working on vaccines against other major infectious diseases while striving to bring the benefits of vaccines into previously unexplored areas. We are at the forefront to usher in a new era of vaccine innovation, both to prevent and treat disease, with special focus on maternal/neonatal, hospital-acquired infections (HAI), and cancer.

Pfizer’s current Vaccines pipeline includes:

  • Phase 3 (Links to
  • Primary Clostridium difficile infection
  • Invasive and non-invasive Pneumococcal infections

Phase 2

  • Invasive and non-invasive pneumococcal infections (PF-06842433)
  • Respiratory Syncytial Virus infection in older adults

Phase 1

  • Prostate Cancer (PF-06753512)
  • Respiratory Syncytial Virus infection (PF-06928316)
  • Invasive Group B streptococcus infection (PF-06760805)
  • Serogroups ABCWY meningococcal infections (PF-06886992)
  • Multiple Cancers (PF-06936308)

Pfizer Vaccines is interested in partnering opportunities in preclinical Vaccines R&D:

Focus on bacterial vaccines, viral vaccines, and cancer vaccines that are in the strategic scope of Pfizer vaccine portfolio

Specific areas of interest in Vaccine Research include:

  • Research tools, reagents, and materials to aid in vaccine discovery
  • Novel viral and bacterial antigens (peptides, proteins, DNA, RNA, glycoconjugates) and expression systems
  • Immunomodulators, adjuvants, delivery platforms, and vector systems to enhance vaccine immune responses
  • Needle-free alternative delivery methods and devices
  • Broad platform technologies for application across multiple programs
  • Vaccine technologies and approaches for non-infectious diseases such as cancer
  • Technology for rapid DNA synthesis and amplification

Specific areas of interest in Vaccine Development include:

  • Formulation compositions and methods to increase vaccine stability and potency
  • Process and assays for vaccine development, testing, and release
  • Improved expression and purification processes to increase production efficiencies